New pharmacoeconomic option in uremic anemia management

Clin Nephrol. 2007 Mar;67(3):200. doi: 10.5414/cnp67200.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Anemia / drug therapy*
  • Anemia / economics
  • Anemia / etiology
  • Cost-Benefit Analysis
  • Darbepoetin alfa
  • Drug Costs*
  • Erythropoietin / analogs & derivatives*
  • Erythropoietin / economics*
  • Erythropoietin / therapeutic use
  • Female
  • Hematinics / economics*
  • Hematinics / therapeutic use
  • Humans
  • Male
  • Recombinant Proteins
  • Uremia / complications*

Substances

  • Hematinics
  • Recombinant Proteins
  • Erythropoietin
  • Darbepoetin alfa